This is a prospective biomarker study that aims at demonstrating the impact of liquid biopsy to deliver better treatment for cancer patients with metastatic disease managed in the community setting
Patients will be selected to present a metastatic cancer (de novo or relapse after primary tumor treatment) eligible for a first line treatment (chemotherapy, immunotherapy, endocrine therapy or targeted therapy). All tumor subtype could be enrolled in the study; metastatic prostate cancer must be resistant to castration. Triple negative breast cancer and Hormone receptor positive, Her2-negative metastatic breast cancer resistant to endocrine therapy are eligible to the study. A plasma sample will be collected at baseline and will be tested for a large panel of gene and MSI status using Next Generation Sequencing (NGS) (cf table). Results will be discussed within a Molecular Tumor Board (MTB) with all declared centers.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
10,000
Patient performs a blood test at treatment baseline
CH de la Côte Basque
Bayonne, France
RECRUITINGProportion of patients for whom ctDNA sequencing
The primary objective of the study will be to evaluate the impact of ctDNA sequencing on the treatment plan of cancer patients managed in satellite centers. This will be performed by estimating the proportion of patients for whom ctDNA sequencing has allowed to propose a systemic treatment that was not considered before the clinician.
Time frame: 72 months
Utilization rates of molecular profiling information
The utilization rates of molecular profiling information (including utilization of information for standard regimens or clinical trials of molecularly targeted therapies)
Time frame: 72 months
Rate of molecular screening failure
Time frame: 72 months
Relapsed time between liquid biopsy and matched therapy onset
Time frame: 72 months
Rate of patients presenting targetable alterations
The rate of patients presenting targetable alterations according to alterations subtypes (copy number/mutation/oncogenic fusions)
Time frame: 72 months
Utilization rate of tumor mutational burden
The utilization rate of tumor mutational burden (TMB - based on new generation sequencing panels)
Time frame: 72 months
Objective Response Rate
Time frame: 72 months
Overall Survival of patients treated with a therapy matched to a targetable alteration and recommended by the MTB based on the ctDNA sequencing
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
CH de Bligny
Bligny, France
RECRUITINGPolyclinique Bordeaux Nord Aquitaine
Bordeaux, France
ACTIVE_NOT_RECRUITINGCH Sud Francilien
Corbeil-Essonnes, France
RECRUITINGCH Annecy Genevois
Épagny, France
ACTIVE_NOT_RECRUITINGGHM de Grenoble
Grenoble, France
ACTIVE_NOT_RECRUITINGCHU de La Réunion
La Réunion, France
RECRUITINGClinique Saint-Jean l'ermitage
Melun, France
ACTIVE_NOT_RECRUITINGHôpital Américain
Neuilly-sur-Seine, France
RECRUITINGHôpital de la source - CHR d'Orléans
Orléans, France
RECRUITING...and 11 more locations
Time frame: 72 months